Shanghai-based cancer drug developer HaiHe Biopharma has raised $146.6 million in a funding round led by Chinese private equity firm Huagai Capital.
Other participants include Hillhouse Capital, Yingke PE, CSPC Pharmaceutical Group, Liansheng Chuangtou, a VC arm under the Chinese Academy of Sciences, and Elite Capital. Huagai was established in 2012...
Rhetoric shaping the debate over China's ambitions to become the prime mover in global technology - and what the US could do in response - reflects the geopolitical significance of the issue. Private equity investors are not immune to its impact
Novo Tellus Capital Partners has invested S$12 million ($8.8 million) in Procurri, a Singapore-listed provider of IT services and data center equipment.
Australia’s Anacacia Capital has realized the final exit from its debut fund with the sale of its majority stake in workplace equipment provider RIS Safety to domestic investor Bricktop Group.
Bain Capital has acquired a majority interest in the data center construction and maintenance division of Shenzhen-listed NetScience Technology for RMB990 million ($147 million).